Note: This is a direct listing on the NASDAQ. This is NOT an IPO. The listing was filed under Global Health Solutions. The company is changing its name to Turn Therapeutics. Existing stockholders are selling the stock in the direct listing. The company is not raising new capital.

Note: Clear Street is the financial advisor. A direct listing does not have an underwriter. A reference price  has not been published. 

We are focused on wound care and dermatology. We are working on getting FDA approval for a new formula of Hexagen to treat eczema and onychomycosis (fungal infection of the nails).

(Note: Turn  Therapeutics made its debut on NASDAQ at $10.00 a share, according to NASDAQ, in a direct listing of up to 17.87 million existing shares on Wednesday, Oct. 8, 2025. No new stock was issued in the direct listing – also known as a direct offering.)

(Background: The registered stockholders of Turn Therapeutics (aka Global Health Solutions) planned to offer up to 17.87 million shares in the NASDAQ direct listing, according to an S-1/A filing dated Sept. 29, 2025. New stock is not being issued. Turn Therapeutics said it expects to start trading on the NASDAQ on Oct. 8, 2025. Background: In its S-1 filing, Turn Therapeutics said its registered stockholders planned to sell up to 8.9 million shares.)